ADJUSTING INSULIN DOSES CONFLICTS OF INTEREST

Similar documents
Therapy Insulin Practical guide to Health Care Providers Quick Reference F Diabetes Mellitus in Type 2

INSULIN TREATMENT FOR TYPE 2 DIABETES MANAGEMENT

Intensifying Insulin Therapy

Diabetes: When To Treat With Insulin and Treatment Goals

INPATIENT DIABETES MANAGEMENT Robert J. Rushakoff, MD Professor of Medicine Director, Inpatient Diabetes University of California, San Francisco

Insulin Initiation and Intensification

A Simplified Approach to Initiating Insulin. 4. Not meeting glycemic goals with oral hypoglycemic agents or

Insulin: Breaking Barriers Enhancing Therapies. Jerry Meece, RPh, FACA, CDE

Diabetes Mellitus 1. Chapter 43. Diabetes Mellitus, Self-Assessment Questions

The basal plus strategy. Denis Raccah, MD, PhD Professor of Medicine University Hospital Sainte Marguerite Marseille FRANCE

Algorithms for Glycemic Management of Type 2 Diabetes

Donovan Victorine Pharm.D. BCACP Clinical Pharmacy Specialist Boise VA Medical Center. U-500 Insulin

Intensive Insulin Therapy in Diabetes Management

Insulin switch & Algorithms Rotorua GP CME June Kingsley Nirmalaraj FRACP Endocrinologist BOPDHB

Managing the U Managing the U Patient as a Surg as a Sur ical Inpatient

A new insulin order form should be completed for subsequent changes to type of insulin and/or frequency of administration

Insulin/Diabetes Calculations

Calculating Insulin Dose

Most patients with T2DM will eventually require insulin therapy. ADA Glycemic Control Targets. What are some of the obstacles?

Insulin Therapy In Type 2 DM. Sources of support. Agenda. Michael Fischer, M.D., M.S. The underuse of insulin Insulin definition and types

Intensifying Insulin In Type 2 Diabetes

Ten Ways to Prevent Insulin-Use Errors in Your Hospital. ASHP Research and Education Foundation May 14, 2014

Lipodystrophy: Metabolic and Clinical Aspects. Resource Room Slide Series

CLASS OBJECTIVES. Describe the history of insulin discovery List types of insulin Define indications and dosages Review case studies

High Dose Insulin Therapy: The case for CONCENTRATED Insulin

Diabetes Medications: Insulin Therapy

Insulin Algorithm for Type 2 Diabetes Mellitus in Children and Adults

Diabetes Management Tube Feeding/Parenteral Nutrition Order Set (Adult)

Starting patients on the V-Go Disposable Insulin Delivery Device

Diabetes and the Elimination of Sliding Scale Insulin. Date: April 30 th Presenter: Derek Sanders, D.Ph.

Insulin Therapy. Endocrinologist. H. Delshad M.D. Research Institute For Endocrine Sciences

Resident s Guide to Inpatient Diabetes

Diabetes Fundamentals

Medical Policy An independent licensee of the Blue Cross Blue Shield Association

Workshop A Tara Kadis

TYPE 2 DIABETES IN CHILDREN DIAGNOSIS AND THERAPY. Ines Guttmann- Bauman MD Clinical Associate Professor, Division of Pediatric Endocrinology, OHSU

Prior Authorization Guideline

Kaiser Sunnyside Medical Center Inpatient Pharmacy Manual

BASAL BOLUS INSULIN FOR MEDICAL- SURGICAL INPATIENTS

SUBJECT: DIABETES MEDICATION MANAGEMENT PROTOCOLS

INSULIN INTENSIFICATION: Taking Care to the Next Level

INSULINThere are. T y p e 1 T y p e 2. many different insulins for

Insulin. Regimens Characteristics / categorization Pharmacokinetics / pharmacodynamics Adverse effects Compatibility Costs

INSULIN ALGORITHM FOR TYPE 2 DIABETES MELLITUS IN CHILDREN 1 AND ADULTS

NCT sanofi-aventis HOE901_3507. insulin glargine

INSULIN AND INCRETIN THERAPIES: WHAT COMBINATIONS ARE RIGHT FOR YOUR PATIENT?

(30251) Insulin SQ Prandial Carbohydrate

TYPE 2 DIABETES SEQUENTIAL INSULIN STRATEGIES

Initiation and Adjustment of Insulin Regimens for Type 2 Diabetes

Inpatient Treatment of Diabetes

MANAGEMENT OF TYPE - 1 DIABETES MELLITUS

INTERNAL MEDICINE RESIDENTS NOON CONFERENCE: INPATIENT GLYCEMIC CONTROL

8/6/2015. Diabetes Educator Needed: Transitioning Inpatient Persons with Diabetes on U-500 Regular Insulin to Discharge Safely

Disclosures. Types of Diabetes Mellitus. Type 1 Diabetes Mellitus. Principles of Basal-Bolus Insulin Therapy and Carbohydrate Counting

Harmony Clinical Trial Medical Media Factsheet

Glycaemic Control in Adults with Type 1 Diabetes

Scottish Medicines Consortium

When and how to start insulin: strategies for success in type 2 diabetes

Add: 2 nd generation sulfonylurea or glinide or Add DPP-4 inhibitor Start or intensify insulin therapy if HbA1c goals not achieved with the above

Present and Future of Insulin Therapy: Research Rationale for New Insulins

User guide Basal-bolus Insulin Dosing Chart: Adult

Insulin Dosing. Meranda Maley, 4 th year PharmD Candidate Florida A & M University Preceptor: Kyle Campbell, PharmD. June 7, 2013

Insulin Analogues versus Pump Therapy in Type 2 Diabetes: Benefits from Pump Therapy

Chapter 2 Subcutaneous Insulin: A Guide for Dosing Regimens in the Hospital

Initiating & titrating insulin & switching in General Practice Workshop 1

Health Professional s. Guide to INSULIN PUMP THERAPY

Treatment Approaches to Diabetes

Objectives PERINATAL INSULIN PUMPS: BASICS FOR NURSES. Historical Perspective. Insulin Pumps in Pregnancy. Insulin Pumps in the US

Glycemic Control Initiative: Insulin Order Set Changes Hypoglycemia Nursing Protocol

Parenteral Dosage of Drugs

Pump Therapy Indications:

There seem to be inconsistencies regarding diabetic management in

Presented By: Dr. Nadira Husein

Primary Care Type 2 Diabetes Update

Case Studies: Initiation and Optimization of Insulin Therapy. Martha Nolte Kennedy, MD UCSF March, 2009

Hospital Guidelines: Inpatient Glycemic Management Guidelines

In-hospital management of diabetes

The first injection of insulin was given on

Mary Bruskewitz APN, MS, RN, BC-ADM Clinical Nurse Specialist Diabetes

Glucose Management University of Colorado Hospital

Challenges in Glycemic Control in Adult and Geriatric Patients. Denyse Gallagher, APRN-BC, CDE Endocrinology Nurse Practitioner

IMPROVED METABOLIC CONTROL WITH A FAVORABLE WEIGHT PROFILE IN PATIENTS WITH TYPE 2 DIABETES TREATED WITH INSULIN GLARGINE (LANTUS ) IN CLINICAL

Diabetes Mellitus. Melissa Meredith M.D. Diabetes Mellitus

Epidemiology of Diabetes (US data released 1/26/2011)

Abdulaziz Al-Subaie. Anfal Al-Shalwi

How To Treat Diabetes

Diabetes in Children and Adolescents

Insulin Administration: What You Don t Know May Hurt Your Patient

Type 2 Diabetes: When to Initiate And Intensify Insulin Therapy. Julie Bate on behalf of: Dr John Wilson Endocrinologist Capital and Coast DHB

Session 5: Insulin: Tried and True - Update on Best Practices in Clinical Use and Patient Adherence Learning Objectives

Insulin: A Practice Update. Department of Nursing Staff Development Elizabeth Borgelt, MS, RN

Transcription:

ADJUSTING INSULIN DOSES CONFLICTS OF INTEREST Vahid Mahabadi, MD Research grants from Sanofi and Amylin Pharmaceutical Companies Mayer B. Davidson, MD Advisory Board Sanofi Pharmaceutical Company Chief Medical Officer Insulin Algorithms, Inc ADJUSTING INSULIN DOSES 1. No one right way 2. Adjust insulin around usual eating pattern not other way around 3. Inconsistent food intake major issue 4. Response to insulin very variable 5. Because of 3 and 4, use pattern of glucose results over time 6. Pre-prandial testing easier than postprandial and usually all that is needed Self-Mixed Insulin Regimen #1 30 NPH/ 10 Reg before breakfast; 20 NPH/10 Reg before dinner: Patient is obese Self-Mixed Insulin Regimen #1 30 NPH/ 10 Reg before breakfast 20 NPH/10 Reg before dinner: Patient is obese Self-Mixed Insulin Regimen #2 80 NPH / 30 Reg before breakfast; 40 NPH / 32 Reg before dinner: Patient is obese Self-Mixed Insulin Regimen #2 80 NPH / 30 Reg before breakfast; 40 NPH / 32 Reg before dinner, Patient is Obese 1

Self-Mixed Insulin Regimen #3 20 NPH / 6 Reg before breakfast; 10 NPH / 8 Reg before dinner; Patient is lean Self-Mixed Insulin Regimen #3 20 NPH / 6 Reg before breakfast; 10 NPH / 8 Reg before dinner: Patient is lean Insulin Therapy Basal & Bolus Vahid Mahabadi, MD, MPH Assistant Professor of Medicine Olive view UCLA Medical Center 12/03/2014 John is a 62 year-old African American man, with type 2 diabetes, diagnosed 10 years ago He works as a electrician and has irregular meal times He tries to avoid sweets He smokes 1 pack a day and drinks 1-2 beers a night He has a history of CAD, depression, & hypertension John reports feeling anxious sometimes for no clear reason; at these times, his hands become clammy and tremble and he becomes sweaty. Height: 6 2, Weight: 234 lbs, BMI: 30 kg/m 2 BP 184/100 mm Hg, HR 90 bpm ROS negative except poor glucose control Current labs: - A1C: 9.4%; - Home glucose ranges: FPG 180-200 mg/dl; premeal 200-250 mg/dl. - Serum creatinine: 2.3 mg/dl, LFTs normal. - - TC 153 mg/dl, LDL 70 mg/dl, HDL 41 mg/dl, TG 225 mg/dl 2

Current medications: o Metformin, 1000 mg BID o Glimepiride, 4 mg QD o Sitagliptin, 100 mg QD o ASA, 81 mg QD o Benazepril, 40 mg QD o Simvastatin, 40 mg QD o Escitalopram, 10 mg QD What do John s symptoms of anxiety, trembling, sweating, and clammy hands suggest? a) Hyperglycemia b) Hypoglycemia c) Hypothyroidism d) GERD John s Self-Blood Glucose Monitoring Download Frequent episodes of hypoglycemia due to sulfonylurea and CKD HbA1c: 9.4% Patient is already on triple therapy with A1C still >9%; likely having hypoglycemia. He should not be on metformin with Cr >1.5 He may continue sitagliptin, as this will decrease potential need for bolus insulin and reduce postprandial glycemic variability; however, due to his increased Cr, his sitagliptin dose should be reduced to 50 mg. Basal insulin should be initiated. John starts with basal analog insulin 10 units at bedtime John was counseled on diet and lifestyle changes including alcohol reduction, smoking cessation, increased physical activity, sodium reduction, and carbohydrate counting He was scheduled for a follow-up visit in 1 week to review BP progress and SMBG results. He was counseled on proper BP home monitoring to ensure accurate readings. 3-month Checkup Height: 6 2, Weight: 228 lbs, BMI: 29 kg/m 2 BP 130/84 mm Hg, HR 68 bpm Foot and fundoscopy exam: no change since prior visit Labs: A1C: 7.9% Serum creatinine: 2.3 mg/dl Urine albumin : 60 mg/g LFTs normal 3

3-month Checkup SMBG Log Current medications: Sitagliptin, 50 mg QD ASA, 81 mg Long acting Insulin 15 units SQ HS & titrate up to 34 u. Benazepril, 40 mg QD Simvastatin, 40 mg QD Escitalopram, 10 mg QD Carvedilol, 12.5 mg BID Time 8:00 (fasting) 1:00 (post-lunch) 5:30 (postdinner) 9:30 (bedtime) BG (mg/dl) 126 Missed reading 210 242 Time 7:30 (fasting) 1:00 (post-lunch) 6:30 (post-dinner) 10:00 (bedtime) BG (mg/dl) 134 214 Missed reading 219 Time 8:00 (fasting) 1:00 (post-lunch) 5:30 (post-dinner) 9:30 (bedtime) BG (mg/dl) 136 229 240 197 What is the best option? a) Increase his basal insulin dose b) Add a rapid-acting insulin with each meal c) Add rapid acting analog to his largest meal d) Switch to premix insulin Options When Not at Goal with One Injection of Basal Insulin Basal Plus Add prandial insulin at main meal or Switch to Basal/Bolus or Switch to a premixed insulin analog Basal Plus Bolus Mealtime Insulin Use rapid-acting analogs, or regular insulin Easier timing, less postprandial hypoglycemia Can be taken up to 15 minutes after starting to eat May start with 1 injection, at largest meal; however most patients need a dose with each meal. 4 units and titrate OR by weight - 0.1 U/kg OR 1 U/15 gr CHO and titrate Titrate to: <140 mg/dl 2 hours post-prandial OR <110 mg/dl next meal or bedtime Stop oral SUs/glinides when prandial insulin is started. Mealtime Insulin Rapid-Acting Analogs (Aspart, Glulisine, Lispro) vs Regular 10 8 Insulin 6 Activity 4 Analog insulin 2 Timing of food absorbed 0 0 1 2 3 4 5 6 7 8 9 10 11 12 Hours Regular Human Insulin Howey DC, et al. Diabetes. 1994;43:396 402. 4

3-month Follow-up Height: 6 2, Weight: 210 lbs, BMI: 27 kg/m 2, BP: 130/78 mm Hg, HR: 80 bpm Foot and fundoscopy exam: no change since prior visit Labs: HbA1c: 6.4%; FPG: 94-100 mg/dl; 2-h PPG: 110-118 mg/dl Serum creatinine: 2.1 mg/dl Urine albumin: 20 mg/g, LFTs normal 3-month Follow-up Current Medications: 40 U long-acting analog insulin SQ hs 12 U rapid-acting insulin SQ with breakfast and lunch 15 U rapid-acting insulin SQ with dinner Benazepril 40 mg QD Simvastatin 40 mg QD Escitalopram 10 mg QD Carvedilol 12.5 mg BID ASA 81 mg QD How to Start Insulin? How to Start Insulin? 2 methods: Weight based or fixed dose. A typical weight-based starting dose ranges from 0.15 to 0.6 Units/kg/day. Usual starting: 0.2-0.5 Units/kg/day. ~ 50% basal & 50% as prandial boluses. Fixed dose: low dose basal (NPH, glargine or detemir), & titrate the dose based on fasting BG. Pre-Mixed (70/30) Insulin Regimen - #1 40 Pre-Mixed before breakfast; 30 Pre-Mixed before dinner: Patient is obese. Pre-Mixed (70/30) Insulin Regimen - #1 40 Pre-Mixed before breakfast; 30 Pre-Mixed before dinner: Patient is obese. 5

Pre-Mixed (70/30) Insulin Regimen - #2 40 Pre-Mixed before breakfast; 30 Pre-Mixed before dinner: Patient is obese. Pre-Mixed (70/30) Insulin Regimen - #2 40 Pre-Mixed before breakfast; 30 Pre-Mixed before dinner, Patient is obese. Pre-Mixed (70/30) Insulin Regimen - #3 60 Pre-Mixed before breakfast; 20 Pre-Mixed before dinner: Patient is obese. Pre-Mixed (70/30) Insulin Regimen - #3 60 Pre-Mixed before breakfast; 20 Pre-Mixed before dinner, Patient is obese. Insulin U-500 Vahid Mahabadi, MD, MPH Assistant Professor of Medicine Olive view UCLA Medical Center 12/03/2014 U-500 Human Regular Insulin: Clinical Pharmacology 1 Clinical experience has shown that U-500 human regular insulin frequently has time action characteristics reflecting both prandial and basal activity. U-500 human regular insulin has an onset within 30 minutes and has a relatively long duration of action (up to 24 hours following a single dose) compared with other regular insulins; this effect has been attributed to the high concentration of the preparation. U-500 human regular insulin is not modified by any agent that might prolong its action. U-500 = 500 units/ml, U-100 = 100 units/ml 1.U-500 Regular Insulin prescribing information, 2013. 6

Potential Candidates for U-500 Human Regular Insulin Therapy 1-3 Patients with the following medical conditions may be considered for U-500 human regular insulin therapy: Type 2 diabetes with obesity and/or severe insulin resistance Type 2 diabetes with insulin requirements >200 units per day Postoperative or post-transplant state High-dose glucocorticoid therapy Severe systemic infection Gestational diabetes mellitus with severe insulin resistance Genetic defects of insulin action Type A insulin resistance syndromes Lipodystrophic diabetes Rare forms of immune-mediated diabetes such as antiinsulin receptor antibodies (type B insulin resistance syndrome) 1.Cochran et al. Diabetes Care 2005;28(5):1240-4. 2.Lane et al. Endocr Pract 2009;15(1):71-9. 3.Segal et al. Am J Health Syst Pharm 2010;67(18):1526-35. U-500 Regular Insulin: Dosage and Administration Recommend use of a U-100 insulin syringe or tuberculin syringe for measurement of dosage 1-3 U-500 regular insulin takes effect within 30 minutes, therefore, it should be followed by a meal within 30 minutes of administration 1-3 U-500 regular insulin should only be administered SC 1,3 Most patients will require 2 or 3 injections daily 1-3 Mixing U-500 regular insulin with other insulins or concurrent use with OADs is not recommended since there are no data to support such use 1 The actual unit dose of U-500 regular insulin does not match the unit markings on a U-100 syringe 1-3 When prescribing U-500 regular insulin, the amount should be written in actual units and unit markings on the U-100 syringe or actual units and volume (ml) if using a tuberculin syringe 1-3 U-500 = 500 units/ml, U-100 = 100 units/ml, OADs: oral antidiabetics, SC: subcutaneously 1.U-500 Regular Insulin prescribing information, 2013. 2.Lane et al. Endocr Pract 2009;15(1):71-9. 3.Segal et al. Am J Health Syst Pharm 2010;67(18):1526-35. Humulin R U-500 Is Highly Concentrated Humulin R U-500 contains 500 units of insulin in each milliliter (5 times more concentrated than Humulin R U-100) Humulin R U-500 allows a patient to inject 1/5 the insulin volume when compared to injecting the same dose of a U-100 insulin 100 units of U-100 insulin in a U-100 syringe (100 unit markings) U-500 = 500 units/ml, U-100 = 100 units/ml 1.U-500 Regular Insulin prescribing information, 2013. = OR 100 units of U-500 insulin in a U-100 insulin syringe (20 unit markings) 100 units of U-500 insulin in a volumetric syringe (0.2 ml) This shows the same dose (actual units) Algorithm for U-500 Regular Insulin Dosing 1,a (1 of 2) TDI Dose (units/day) b 150-300 Injection Frequency/ Delivery Method c 2 injections/day (before breakfast and evening meal) 3 injections/day (before meals) CSII (1 pump unit = 0.01 ml; 0.01 ml of U-500R insulin = 5 actual units) Dosage Distribution (% of TDD) d 60/40 or 50/50 40/30/30 or 33.3/33.3/33.3 3 mealtime boluses (50% TDD) with basal rate (50% TDD) U-500 = 500 units/ml, U-100 = 100 units/ml, TDI: total daily insulin, CSII: continuous subcutaneous insulin infusion, U-500R: U-500 regular human insulin, TDD: total daily dose (of insulin), A1C: glycated hemoglobin a Simplified algorithm for conversion from previous TDD of U-100 insulins to U-500 regular insulin b When switching to U-500 regular insulin, the TDD may be reduced by 10%-20% for initial A1C 8%; increasing the dose by 10% to 20% for initial A1C 10% may be considered c U-500 regular boluses are recommended 30 minutes before a meal; dosage may be titrated according to frequent self-monitored blood glucose d May initially use fixed ratios or distribute boluses according to the proportion of carbohydrates with meal or carbohydrate-counting according to patient preference and physician judgment 1.Cochran et al. Diabetes Educ 2014;40(2):153-65. Algorithm for U-500 Regular Insulin Dosing 1,a (2 of 2) TDI Dose (units/day) b 300-600 Injection Frequency/ Delivery Method c 3 injections/day 4 injections/day (before meals and bedtime) CSII (1 pump unit = 0.01 ml; 0.01 ml of U-500R insulin = 5 actual units) Dosage Distribution (% of TDD) d 40/30/30 or 33.3/33.3/33.3 30/30/30/10 3 mealtime boluses (50% TDD) with basal rate (50% TDD) >600 4 injections/day 30/30/30/10 U-500 = 500 units/ml, U-100 = 100 units/ml, TDI: total daily insulin, CSII: continuous subcutaneous insulin infusion, U-500R: U-500 regular human insulin, TDD: total daily dose (of insulin), A1C: glycated hemoglobin a Simplified algorithm for conversion from previous TDD of U-100 insulins to U-500 regular insulin b When switching to U-500 regular insulin, the TDD may be reduced by 10%-20% for initial A1C 8%; increasing the dose by 10% to 20% for initial A1C 10% may be considered c U-500 regular boluses are recommended 30 minutes before a meal; dosage may be titrated according to frequent self-monitored blood glucose d May initially use fixed ratios or distribute boluses according to the proportion of carbohydrates with meal or carbohydrate-counting according to patient preference and physician judgment 1.Cochran et al. Diabetes Educ 2014;40(2):153-65. # 1 Norman is 48 yo male with T2DM for ~ 15 years. His weight is 228 Ibs with BMI of 36.4. PMHX: Dyslipidemia, HTN, Obesity, & Asthma. Enrolled in DMP first 10/10/11 & completed at HbA1c 7.3% Second enrollment, 5/2012, with HbA1c 10.9% Initial regime: NPH 40 units AM, and 40 units HS Reg 20 units am and 20 units HS + SS Metformin 1000 mg BID AC meals Pioglitazone 15 mg daily. 7

# 1 Blood glucose values at the time of referral (while on 165 units daily): FBS 275 233 139 194 235 189 241 Pre Dinner 282 238 127 121 201 155 179 # 1 Barriers to control: Incorrect timing of meds (both Metformin and insulin) Complaining of painful injection & nightmares. From 10/2013-2/6/14 titrated insulin, Pioglitazone stopped & had patient taking at correct time yet BG control remained elevated. 2/6/14 Insulin switched to RU-500 TDD of NPH/REG= (at time of insulin switch) was 178 units and HbA1c was 9.8%. # 1 Blood glucose values at the time, which switched to RU-500 at 17 units AC BF & D: FBS 138 111 141 104 98 106 102 Pre Dinner 145 124 134 140 181 126 128 # 1 Started on RU-500 at 17 insulin syringe units (85 units) BID AC BF & D. Within 2 months HbA1c dropped to 6.8% & currently 6.6%. Norman still reports weekly and SMBG is stable. Ongoing problems with his diet/activity but better & improving. U-500 Regular Insulin: Safety 1 Fluid retention and heart failure with concomitant use of PPAR-gamma agonists Thiazolidinediones, which are PPAR-gamma agonists, can cause dose-related fluid retention, particularly when used in combination with insulin Fluid retention may lead to or exacerbate heart failure. Patients treated with insulin, including Humulin R U-500 and a PPAR-gamma agonist, should be observed for signs and symptoms of heart failure. # 2 Steven, 56 yo male with h/o T2 DM for ~ 18 years. 3 rd enrollment in DMP- previously completed not at goal X 2 Referred once again on 12/2013 with HbA1c 11.4%. On insulin glargine 45 units BID & insulin Lispro 40 units AC BF/L/D with TDD 210 units (with 5 injections daily). Learned pt non adherent to diet, weight gain, injecting incorrectly at times (post vs. pre meals) 1.U-500 Regular Insulin prescribing information, 2013. 2. Lane et al. Endocr Pract 2009;15(1):71-9. 3. Segal et al. Am J Health Syst Pharm 2010;67(18):1526-35. 8

# 2 # 2 Blood glucose values at the time of re: FBS 281 198 188 211 175 186 208 Pre Dinner 212 241 341 410 218 261 182 12/2013 started on RU-500 at enrollment due to high TDD and poor control with multiple daily injections. Starting dose: 20 syringe units BID (100 actual units) AC BF & Dinner. Current dose: 32 syringe units am (160 units) am and 24 syringe units pm (120 units) Current HbA1c 6.6% and SMBG stable- NO hypos. 9